- Open Access
Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer
© Foerster et al. 2015
- Received: 7 June 2015
- Accepted: 7 July 2015
- Published: 15 July 2015
Bone metastases are an important clinical issue in women with breast cancer. Particularly, unstable spinal bone metastases (SBM) are a major cause of severe morbidity and reduced quality of life (QoL) due to frequent immobilization. Radiotherapy (RT) is the major treatment modality and is capable of promoting re-ossification and improving stability. Since local therapy response is excellent, survival of these patients with unstable SBM is of high clinical importance. We therefore conducted this analysis to assess survival and to determine prognostic factors for bone survival (BS) in women with breast cancer and unstable SBM.
A total population of 92 women with unstable SBM from breast cancer who were treated with RT at our department between January 2000 and January 2012 was retrospectively investigated. We calculated overall survival (OS) and BS (time between first diagnosis of bone metastases until death) with the Kaplan-Meier method and assessed prognostic factors for BS with a Cox regression model.
Mean age at first diagnosis of breast cancer was 60.8 years ± SD 12.4 years. OS after 1, 2 and 5 years was 84.8, 66.3 and 50 %, respectively. BS after 1, 2 and 5 years was 62.0, 33.7 and 12 %, respectively. An age > 50 years (p < .001; HR 1.036 [CI 1.015–1.057]), the presence of a single bone metastasis (p = .002; HR 0.469 [CI 0.292–0.753]) and triple negative phenotype (p < .001; HR 1.068 [CI 0.933–1.125]) were identified as independent prognostic factors for BS.
Our analysis demonstrated a short survival of women with breast cancer and unstable SBM. Age, presence of a solitary SBM and triple-negative phenotype correlated with survival. Our results may have an impact on therapeutic decisions in the future and offer a rationale for future prospective investigations.
- Bone metastases
- Breast cancer
Metastases in women with breast cancer most frequently occur in the skeleton . Up to 2.6 % of all breast cancer patients already present with bone metastases at initial diagnosis and up to 15 % will develop bone metastases within 15 years [2, 3]. Particularly, metastases of the spinal column are a major cause of severe morbidity and reduced quality of life due to severe pain, pathological fractures, spinal cord compression and hypercalcemia [4, 5]. Additionally patients with unstable spinal bone metastases (SBM) are often immobilized or prescribed an orthopedic corset for the prevention of vertebral fractures and possible spinal cord compression. Treatment of SBM is multimodal including radiotherapy (RT), surgery and systemic treatments such as bisphosphonates . Most commonly patients are treated with RT [7, 8] and a frequent treatment indication is instability . In previous studies we were able to show that RT is capable of promoting re-ossification leading to increased stability of SBM. In those studies the analyzed patients showed only minor cancer-related morbidity during follow-up and reached comparably high survival rates. Additionally, we showed that the use of a validated scoring system to assess the stability of spinal bone metastases may prevent physicians from overdiagnosis of instability [10–12]. Since local therapy response is excellent, survival represents a major clinical interest in these patients with unstable SBM. Therefore, we conducted this analysis to assess survival and to determine prognostic factors for bone survival (BS) in women with unstable SBM from breast cancer.
Age (mean, SD)
Chemotherapy before RT
Radiological response at 3 months after RT
Radiological response at 6 months after RT
Number of metastases
Pathological fracture before RT
BS was defined as the time from initial diagnosis of SBM until death from any cause. The time of site irradiation was not equal to the time of initial diagnosis of bone metastases. Overall survival (OS) was defined as time from initial diagnosis of breast cancer until death from any cause. We estimated patients’ survival using the Kaplan-Meier method. Patients were censored on the basis of whether or not they were alive. Results were reported as the p-values of the log-rank tests. Multivariate analysis was performed to detect factors independently associated with BS using a Cox proportional hazards model. This regression analysis was performed by including the factors age (>50 years), Karnofsky Performance Status score (≤70 %), chemotherapy (ChT) prior to RT (no ChT), number of metastases (solitary metastasis), local response (response after 3 or 6 months), concomitant bisphosphonates (no bisphosphonates), orthopedic corset (no corset) and pathological fractures (no fracture). The results were reported as p-values, hazard ratios and 95 % confidence intervals (CI). For all analyses, a p-value of 0.05 or less was considered statistically significant. All statistical analyses were done using the SAS software version 9.3 (SAS Institute, Cary, NC, USA).
RT was carried out at the clinic of our department. After CT-assisted three-dimensional-simulation, RT was performed with 2-3 dorsal photon beams in the 6-MV energy range. The planning target volume (PTV) covered the specific vertebral body affected, as well as those immediately above and below it. The median individual dose in all patients was 3 Gy; the median total dose 30 Gy. The respective fraction and total doses were planned separately for each individual patient, depending on tumor histology, the patient’s general state of health, the current staging and respective prognosis.
Cox regression model of prognostic factors for bone survival
95 % CI
Number of metastases
Breast cancer patients suffering from bone metastases of the spine represent a large patient group at most RT facilities. An important indication for RT treatment in these patients is instability, which is often associated with increased pain, profoundly reduced activity in daily life (ADL) and consequently severely impaired QoL. Unstable SBM may therefore be associated with shortened survival. We found OS and BS to be substantially shorter in our analysis with only 50 and 12 %, respectively, alive after 5 years compared to our previous study on osteolytic SBM in women with breast cancer . Further studies have reported even worse survival rates in women with bone metastases , but this may be explained by a selection bias of only including patients with a follow-up of at least 6 months in our study. In an earlier small prospective study we already reported even lower survival rates in a population of patients with unstable metastases from various solid tumors . In another study on patients with metastatic lung cancer we did not find any difference in survival between patients with stable and unstable SBM . We believe that this was due to the extremely short survival time of those patients with metastatic lung cancer. Women with metastatic breast cancer have a more favorable prognosis than those with other solid tumors, e.g. lung cancer, and instability, possibly due to its associated morbidity, seems to be a relevant factor for long-term survival.
We found an age of more than 50 years, the presence of multiple SBM and triple negative phenotype to be associated with a worse prognosis after first diagnosis of bone metastases. In a recent study Bollen et al.  reported a median survival time of 22.5 months (95 % CI 18.0–26.9) for the receptor positive category and 6.7 months (95 % CI 2.4–10.9) for the triple negative category (p < 0.001). Therefore, patients with bone metastases from triple negative breast cancer have a significantly worse prognosis than those with a receptor positive phenotype.
According to the literature, another important prognostic factor for survival is the existence of additional extra-skeletal metastases . In our analysis we were only able to demonstrate the prognostic relevance of age, the presence of a solitary metastasis and triple-negative phenotype. We believe this to be due to the small number of women with extra-skeletal metastases in our study cohort.
This analysis demonstrated a short survival of breast cancer patients with unstable SBM. Importantly, we presented a correlation between age, presence of a solitary metastasis, triple-negative phenotype, and survival. This may have an impact on therapeutic decisions in the future. The results offer a rationale for future prospective investigations.
We acknowledge the financial support of Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universität Heidelberg within the funding program Open Access Publishing.
- Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79:965–76.PubMedView ArticleGoogle Scholar
- Hagberg KW, Taylor A, Hernandez RK, Jick S. Incidence of bone metastases in breast cancer patients in the United Kingdom: results of a multi-database linkage study using the general practice research database. Cancer Epidemiol. 2013;37:240–6.PubMedView ArticleGoogle Scholar
- Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2013;13:88–94.PubMedView ArticleGoogle Scholar
- Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters Jr RS, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009;12:417–26.PubMedView ArticleGoogle Scholar
- Whyne CM, Hu SS, Lotz JC. Biomechanically derived guideline equations for burst fracture risk prediction in the metastatically involved spine. J Spinal Disord Tech. 2003;16:180–5.PubMedView ArticleGoogle Scholar
- Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112–24.View ArticleGoogle Scholar
- Mitera G, Probyn L, Ford M, Donovan A, Rubenstein J, Finkelstein J, et al. Correlation of computed tomography imaging features with pain response in patients with spine metastases after radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81:827–30.PubMedView ArticleGoogle Scholar
- Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol). 2006;18:539–44.View ArticleGoogle Scholar
- Souchon R, Feyer P, Thomssen C, Fehm T, Diel I, Nitz U, et al. Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer. Breast Care (Basel). 2010;5:401–7.View ArticleGoogle Scholar
- Foerster R, Habermehl D, Bruckner T, Bostel T, Schlampp I, Welzel T, et al. Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol. 2014;9:194.PubMed CentralPubMedView ArticleGoogle Scholar
- Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer—a retrospective analysis of 338 cases. Radiat Oncol. 2013;8:200.PubMed CentralPubMedView ArticleGoogle Scholar
- Schlampp I, Rieken S, Habermehl D, Bruckner T, Forster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol. 2014;190:792–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia Univ Press; 1949. p. 196.Google Scholar
- Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine (Phila Pa 1976). 1997;22:239–45.View ArticleGoogle Scholar
- Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21:3279–86.PubMedView ArticleGoogle Scholar
- Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy—a prospective trial. Radiat Oncol. 2014;9:133.PubMed CentralPubMedView ArticleGoogle Scholar
- Rief H, Muley T, Bruckner T, Welzel T, Rieken S, Bischof M, et al. Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases: a retrospective analysis of 303 patients. Strahlenther Onkol. 2014;190:59–63.PubMedView ArticleGoogle Scholar
- Bollen L, Wibmer C, Wang M, van der Linden YM, Leithner A, Bunger CE, et al. Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases. Clin Exp Metastasis. 2015;32:1–5.PubMedView ArticleGoogle Scholar
- Ahn SG, Lee HM, Cho SH, Lee SA, Hwang SH, Jeong J, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J. 2013;54:1168–77.PubMed CentralPubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.